The head of Federal Antimonopoly Service (FAS) of Russia Igor Artemyev met with the executives of Pharmstandard PJSC and BIOCAD CJSC, two major Russian pharmaceutical companies.
At their meeting, the parties discussed the ways to support the domestic pharmaceutical manufacturers in the draft Decree of the Government of the Russian Federation “On State Registration and Re-Registration of Maximum Ex-Works Prices for Medicinal Products Included in the List of Vital and Essential Drugs” which is currently being elaborated.
The discussion allowed to understand the need for supporting the Russian manufacturers in the registration of prices for medicinal products to the extent provided by the laws of the Russian Federation. This includes a 15% preference to Russian manufacturers in accordance with the article 14 of the Law on the Contract System and the Order No. 155 of the Ministry of Economic Development. It means that, at their registration, the prices of Russian-made generics will be reduced by 15% less than the prices of foreign-manufactured generics compared to the prices of relevant reference drugs.
The parties also discussed how to use the information on prices in reference countries during the registration of maximum ex-works prices. The discussion resulted in the decision to develop the criteria for the used sources of information on prices and further discuss with the representatives of pharmaceutical market whether it would be advisable to calculate the maximum ex-works prices based on three minimum prices in reference countries in order to eliminate the impact of abnormally low prices on the prices registered in Russia.